Skip to content
FrontierPicks

Watching

NTLA · Intellia Therapeutics

Conviction · Low · not more likely to lead the S&P 500 over the next three months

Note written ·

The last three months

Down 20.4% since the close; the S&P 500 is down 9.4% over the same sessions. Figures in the note can cover a different window.

NTLA daily closes from 24 August 2026 to 20 November 2026, last $10.00, with its price line set under the older rule: a daily close above $12.00; 50-day average $11.67 on 20 November 2026. 24 August 2026: $12.56; 50-day average $13.2925 August 2026: $13.51; 50-day average $13.3226 August 2026: $13.19; 50-day average $13.2927 August 2026: $13.11; 50-day average $13.2628 August 2026: $12.87; 50-day average $13.2131 August 2026: $12.73; 50-day average $13.151 September 2026: $12.69; 50-day average $13.092 September 2026: $12.76; 50-day average $13.043 September 2026: $12.68; 50-day average $12.994 September 2026: $12.74; 50-day average $12.928 September 2026: $12.74; 50-day average $12.849 September 2026: $12.21; 50-day average $12.7510 September 2026: $11.93; 50-day average $12.6511 September 2026: $11.74; 50-day average $12.5414 September 2026: $11.87; 50-day average $12.4315 September 2026: $11.36; 50-day average $12.3016 September 2026: $11.49; 50-day average $12.1817 September 2026: $12.26; 50-day average $12.0918 September 2026: $12.14; 50-day average $12.0221 September 2026: $12.22; 50-day average $11.9822 September 2026: $12.69; 50-day average $11.9823 September 2026: $12.33; 50-day average $11.9624 September 2026: $12.16; 50-day average $11.9425 September 2026: $11.75; 50-day average $11.9428 September 2026: $11.42; 50-day average $11.9429 September 2026: $12.03; 50-day average $11.9630 September 2026: $12.06; 50-day average $11.971 October 2026: $12.12; 50-day average $11.992 October 2026: $12.26; 50-day average $12.025 October 2026: $12.75; 50-day average $12.066 October 2026: $12.37; 50-day average $12.097 October 2026: $11.71; 50-day average $12.118 October 2026: $12.60; 50-day average $12.149 October 2026: $13.07; 50-day average $12.1812 October 2026: $12.58; 50-day average $12.2213 October 2026: $11.91; 50-day average $12.2414 October 2026: $11.43; 50-day average $12.2515 October 2026: $11.34; 50-day average $12.2516 October 2026: $11.42; 50-day average $12.2619 October 2026: $11.58; 50-day average $12.2520 October 2026: $11.84; 50-day average $12.2521 October 2026: $11.65; 50-day average $12.2422 October 2026: $11.16; 50-day average $12.2223 October 2026: $11.21; 50-day average $12.2126 October 2026: $11.26; 50-day average $12.1927 October 2026: $12.28; 50-day average $12.2028 October 2026: $13.32; 50-day average $12.2329 October 2026: $13.23; 50-day average $12.2330 October 2026: $12.47; 50-day average $12.232 November 2026: $11.66; 50-day average $12.213 November 2026: $11.86; 50-day average $12.204 November 2026: $12.31; 50-day average $12.175 November 2026: $11.10; 50-day average $12.136 November 2026: $11.35; 50-day average $12.099 November 2026: $12.11; 50-day average $12.0810 November 2026: $11.17; 50-day average $12.0511 November 2026: $11.41; 50-day average $12.0212 November 2026: $10.55; 50-day average $11.9813 November 2026: $9.70; 50-day average $11.9216 November 2026: $9.86; 50-day average $11.8617 November 2026: $9.78; 50-day average $11.8018 November 2026: $9.77; 50-day average $11.7519 November 2026: $9.52; 50-day average $11.7020 November 2026: $10.00; 50-day average $11.67

Daily closes, to . Red: the note's price line under the older rule, a daily close above $12.00, set on 20 November 2026. The pale line is the 50-day average, $11.67 on .

Price line

A daily close above $12.00, back over the 50-day average, which would show the shares leading into the 10 March 2027 FDA decision; or an FDA approval of lonvo-z before that date.

A price line, set under the rules before kill lines became business results on 20 November 2026. It stays until the note's next read replaces it; a close through it only makes the note due for a fresh read.

Research onlyNot in the portfolio.

The portfolio's record →

The business · as of

Intellia develops one-time CRISPR gene-editing treatments delivered inside the body: lonvo-z for hereditary angioedema and nex-z, with Regeneron, for transthyretin amyloidosis. It has no product sales yet. Revenue comes from collaborations: $7.2 million in the quarter to 30 September 2026.

What is changing, and what follows · as of

What is changing now
In September 2026 the FDA accepted the lonvo-z application with Priority Review and set a 10 March 2027 action date, the company reported on 5 November 2026; it plans a US launch in the first quarter of 2027.
What follows for the company
General and administrative expense rose to $46.1 million in the third quarter of 2026 from $30.5 million a year earlier as the company built its field force; the net loss widened to $127.5 million.
What follows for its customers, suppliers and competitors
If approved, lonvo-z competes with Takeda (TAK), BioCryst (BCRX), Ionis (IONS) and KalVista (KALV) in HAE; Regeneron (REGN) shares nex-z economics, and its revenue to Intellia fell in the quarter.

What the price assumes · as of

At the 19 November 2026 close (filed inputs to 5 November 2026) the shares trade at EV/sales 17.7 and P/B 2.2, for an enterprise value of $936 million and a free-cash-flow yield of −26.8%. That holds only if lonvo-z wins approval and a launch revenue ramp starts to close a free cash outflow of $358 million over four quarters.

Key figures from the filings · Health Care

Quarter to 30 September 2026, filed 5 November 2026; valuation at the 20 November 2026 close

The last six quarters

Revenue and its change on a year over the six quarters to 30 September 2026, from the company's filings with the SEC, the latest filed 5 November 2026. Operating margin is not drawn: in at least one quarter it is below −100%, beyond the chart's scale. All filed numbers, below, lists every quarter.
Revenue, latest quarter ($M)
7.2
Revenue, change on a year (%)
−48.0
Operating margin (%)
−1707.7
Free cash flow, four quarters ($M)
−358
Net cash, cash less debt ($M)
400
Enterprise value to sales (×)
19.0
Free-cash-flow yield (%)
−25.5
All filed numbers

What Intellia Therapeutics reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .

Results by quarter Each quarter with the day its figures were first filed, and the day of a later filing that changed them; no gross margin is reported
Quarter to Revenue ($M) On a year (%) Operating margin (%)
first filed 7.2 −48.0 −1707.7
first filed 7.7 −46.2 −1472.3
first filed 15.0 −9.5 −668.1
first filed 23.0 +78.8 −428.9
first filed 13.8 +51.3 −808.9
first filed 14.2 +104.8 −772.2
Income Quarter to 30 September 2026, filed 5 November 2026
Pre-tax income ($M) Not reported
Net income ($M) four quarters: −426 −128
Diluted shares, change on a year (%) against the quarter to 30 September 2025 +27.2
Cash flow Four quarters to 30 September 2026, filed 5 November 2026
Operating cash flow ($M) −355
Capital spending ($M) 2.9
Free cash flow ($M) −358
Balance sheet At 30 September 2026, filed 5 November 2026
Cash and short-term investments ($M) 474
Debt ($M) long-term debt 73.7
Net cash, cash less debt ($M) 400
Deferred revenue ($M) −100.0% on a year 0.0
Backlog, orders not yet delivered ($M) Not reported
Receivables ($M) 7.5
Inventory ($M) Not reported
Shareholders' equity ($M) 613
Valuation At the 20 November 2026 close, filed figures to 5 November 2026
Market value ($M) 1,404
Enterprise value, market value plus net debt ($M) 1,003
Enterprise value to sales (×) 19.0
Enterprise value to operating income (×) Not meaningful
Price to earnings (×) Not meaningful
Price to book value (×) 2.3
Free-cash-flow yield (%) −25.5

Short interest (FINRA, settled 30 October 2026, published 10 November 2026): 31.6% of shares outstanding sold short, 11.1 days of average trading to cover, −0.2% since the previous report.

Insiders' open-market trades SEC Form 4, by trade date
Window Bought Sold
90 days Not available yet Not available yet
12 months Not available yet Not available yet

Linked companies · as of

Customers:
REGN
Competitors:
TAK, BCRX, IONS, KALV, ALNY, BBIO, PFE

The thesis

Intellia Therapeutics is more likely to lag the S&P 500 over the next three months. Its main value event, the FDA decision on lonvo-z (lonvoguran ziclumeran) for hereditary angioedema (HAE), is due on 10 March 2027. That date falls just after the 63-session window. Until then the shares carry a cash burn of $358 million over four quarters and partner revenue that is shrinking. The rating is Low because the shares fell after good news. Positive lonvo-z data at the ACAAI meeting on 12 November 2026 were followed by a close of $9.70 on 13 November 2026, down from $10.55 the session before.

The drug looks strong on its own terms. The company's 5 November 2026 results release says the FDA accepted the Biologics License Application (BLA) in September with Priority Review and does not plan an advisory committee. It also says the company plans a US launch in the first quarter of 2027. The near-term problem is the gap between that approval and any revenue. In the meantime, the filed numbers show losses getting wider and the share count rising.

Bullish and bearish views on Intellia Therapeutics, Inc.

The bull case on Intellia Therapeutics, Inc. (NTLA), in brief: Priority Review, with no advisory panel planned. The bear case: partner revenue is falling fast.

Bull case

  • Priority Review, with no advisory panel planned. The FDA set a target action date of 10 March 2027 and told the company it is not planning an advisory committee, according to the 5 November 2026 third-quarter release.
  • Data that support a one-time treatment. Citizens reported on 13 November 2026 that two-thirds of patients in the ACAAI 2026 update were attack-free and 100% were free of long-term preventive therapy. The firm kept its $30 target and assigns $20 a share to the HAE opportunity.
  • Funding reaches beyond the launch. The company reported $614.8 million in cash, equivalents and marketable securities at 30 September 2026. It says that funds operations at least into 2028, before lonvo-z revenue and before further draws on an OrbiMed term loan of up to $400 million signed in September 2026.
  • Second Phase 3 program fully enrolled. MAGNITUDE-2, which tests nex-z (nexiguran ziclumeran) in hereditary transthyretin amyloidosis with polyneuropathy, finished enrolling in the third quarter of 2026 with more than the targeted 60 patients, per the 5 November 2026 release.

Bear case

  • Partner revenue is falling fast. Collaboration revenue was $7.2 million in the quarter to 30 September 2026, down 48.0% from a year earlier. The company attributes the drop mainly to lower revenue from Regeneron.
  • Losses widen as launch costs build. The third-quarter net loss was $127.5 million, against $101.3 million a year earlier. General and administrative expense rose to $46.1 million from $30.5 million, while research spending fell to $83.3 million from $94.7 million (5 November 2026 release).
  • Dilution and new debt. Diluted shares rose 27.2% from a year earlier in the quarter to 30 September 2026. The 10-Q filed 5 November 2026 shows $74 million of long-term debt.
  • Most analysts are cautious. BofA Securities kept a Hold rating on 14 November 2026. JPMorgan raised its target to $9 from $8 on 9 November 2026, which is below the 19 November 2026 close of $9.52.
  • Planned insider selling continues. SEC Form 4 filings show the chief executive sold 9,000 shares at $11.99 on 2 November 2026 and 22,675 shares at an average of $12.65 on 20 August 2026 and 21 August 2026, all under a Rule 10b5-1 plan.

Price setup · as of

Intellia closed at $9.52 on 19 November 2026. That is 48.5% below the 52-week intraday high of $18.48 set on 2 July 2026. On adjusted daily closes, the shares sit below the 50-day average of $11.70 and the 200-day average of $12.89, and they are down 25.9% over three months from a reference close of $12.84 on 21 August 2026.

The latest fall came after good news. The shares closed at $10.55 on 12 November 2026, the day of the ACAAI data and the investor webcast, then fell to $9.70 on 13 November 2026. They have stayed between $9.52 and $9.86 since. The 52-week closing low is $8.04 from 20 November 2025.

A common market view is that biotech shares drift lower before an FDA decision and then rally into it. Across US stocks, no reliable effect has been found so far after one-day drops of this kind. The case therefore rests on the calendar and on the cash figures.

Catalysts ahead

  • 7 December 2026: Intellia at the 23rd Global Cardiovascular Clinical Trialists Forum, Washington, D.C. (7 December to 9 December 2026). Any update on the timing of the nex-z Phase 3 trial in cardiomyopathy would change how much value sits beyond lonvo-z.
  • ~26 February 2027 (est.): Fourth-quarter and full-year 2026 results. Shows the year-end cash, the term-loan draws and the 2027 spending plan going into launch.
  • 10 March 2027: FDA target action date for lonvo-z in hereditary angioedema. Approval and the approved label decide whether the planned first-quarter 2027 launch happens; this is the event the case turns on.

What it trades with · as of

The shares trade on events: the FDA date, data presentations and launch news. Partner economics matter too, because Regeneron (REGN) co-develops nex-z and was the main source of the revenue decline. In HAE, lonvo-z would compete with preventive treatments from Takeda (TAK), BioCryst (BCRX) and Ionis (IONS) and with KalVista's (KALV) on-demand therapy. In transthyretin amyloidosis, nex-z would face Alnylam (ALNY), BridgeBio (BBIO) and Pfizer (PFE). How investors price gene-editing companies in general also moves the shares.

Caveats

  • Intellia reports no product revenue; all revenue is from collaborations, so quarterly revenue reflects partner accounting rather than demand. Form 10-Q for the third quarter of 2026 · as of
  • The company has a secured term loan facility of up to $400 million with OrbiMed, and diluted shares rose 27.2% from a year earlier in the third quarter of 2026. Form 10-Q for the third quarter of 2026 · as of
The evidence, claim by claim (8)
  1. The FDA accepted the lonvo-z Biologics License Application with Priority Review and a target action date of 10 March 2027, and is not currently planning an advisory committee. Intellia third-quarter 2026 results release (8-K exhibit 99.1) · as of
  2. Collaboration revenue was $7.2 million in the third quarter of 2026, against $13.8 million a year earlier, mainly because of lower Regeneron revenue. Intellia third-quarter 2026 results release (8-K exhibit 99.1) · as of
  3. The third-quarter 2026 net loss was $127.5 million, against $101.3 million a year earlier; general and administrative expense rose to $46.1 million from $30.5 million. Intellia third-quarter 2026 results release (8-K exhibit 99.1) · as of
  4. Cash, equivalents and marketable securities were $614.8 million at 30 September 2026, which the company says funds operations at least into 2028. Intellia third-quarter 2026 results release (8-K exhibit 99.1) · as of
  5. In September 2026 Intellia signed a senior secured term loan facility of up to $400 million with OrbiMed. Intellia third-quarter 2026 results release (8-K exhibit 99.1) · as of
  6. Citizens kept a Market Outperform rating and a $30 target after the ACAAI lonvo-z data, citing two-thirds of patients attack-free. Investing.com, Citizens note report · as of
  7. JPMorgan raised its Intellia price target to $9 from $8. CNN Markets analyst summary · as of
  8. The chief executive sold 9,000 shares at $11.99 on 2 November 2026 under a Rule 10b5-1 plan. SEC Form 4 filed 3 November 2026 · as of

Sources

Related · shared themes

Every buy and sale, with its reason, is published in the portfolio feed. Follow the portfolio feed → Follow @frontierpicks on X